US President Trump announced 100-200% tariffs on generic medicines from Aug 2028 unless manufacturing relocates to the US. This poses a significant challenge for India's $30B pharma industry, which supplies 47% of US generic prescriptions, potentially making exports unviable and raising US drug prices.
The FDA's Pharmacy Compounding Advisory Committee meets Thursday for two days to recommend on allowing compounding pharmacies to make popular injectable peptides like TB-500 and BPC-157. This decision is critical amidst safety concerns, lack of large-scale human trials, and industry pressure to lift current restrictions.
Donald Trump's proposed 200% tariff on generic drug imports raises concerns for Indian pharma, but experts suggest a limited long-term impact due to India's cost advantage, US dependence on imports, and lengthy factory approval timelines, making large-scale manufacturing shifts difficult.
US President Donald Trump's proposed tariffs of up to 200% on imported generic medicines could pressure Indian pharmaceutical exporters, but India's cost advantage may help many drugs remain competitive in the US market, according to the Global Trade Research Initiative (GTRI).
President Trump plans 100-200% tariffs on generic drugs by 2028 to reshore production, impacting Indian pharma. US and China are set for AI talks amid IP theft concerns. US strikes Iran for an 11th night as Secretary Rubio questions Iran's seriousness in peace talks. Alphabet and Tesla earnings are also due.
China's NMPA has approved a rare-disease therapy for commercial sales to treat narcolepsy type 1 in individuals aged 16 and older. The unnamed drug previously received fast-track status in the US and orphan-drug designation in Japan and the EU, indicating international recognition for its importance.
US-Präsident Donald Trump droht Arzneimittelfirmen mit 100 bis 200 Prozent Zöllen auf Generika ab Sommer 2028, um die Produktion in die USA zu verlagern. Zuvor hatte er bereits Zölle auf patentgeschützte Marken-Arzneimittel angekündigt.
San Diego-based Axiom Biosciences plans a "contrarian" Hong Kong IPO in 2027, followed by a 2029 U.S. listing, to access sophisticated biotech investors and Asian partners. This move contrasts with the traditional trend of Chinese firms listing in the U.S., highlighting Hong Kong's growing appeal as a biotech fundraising hub despite U.S. market depth.
Novo Nordisk is suing Eli Lilly, alleging "false and misleading" advertisements for its weight-loss and anti-diabetes treatments, Zepbound and Mounjaro. Novo Nordisk claims Lilly used outdated studies comparing its highest doses against lower doses of Novo Nordisk's drugs, creating a deceptive impression of superiority. Eli Lilly defends its ads, citing the Surmount-5 trial as the only direct comparison.
A new study, published in the Australian Journal of Rural Health, has mapped Australia's "pharmacy deserts" for the first time, identifying areas with low community pharmacy density. Findings show fewer services in remote Northern Territory communities, outer-city Melbourne and Perth, and specific rural towns, with Australia's average density below the global average.
Zwei führende Pharmaunternehmen, Boehringer Ingelheim und Eli Lilly, haben im Juni fast zeitgleich Investitionsstopps in Deutschland angekündigt. Dies geschah als Reaktion auf ein neues Gesetz von Bundesgesundheitsministerin Nina Warken, das höhere Herstellerabschläge und ein Preismoratorium für Impfstoffe vorsieht und die Branche finanziell stark belastet.
UK-based healthcare billing software maker Craneware announced a cyberattack resulted in the theft of a "significant volume" of customer, employee, and partner data. The breach affects a company whose software is widely used in the U.S. healthcare sector, and its investigation is ongoing.
China's market approvals in the first half of the year were dominated by domestically produced novel drugs, accounting for over 80% of clearances. This includes CARsgen Therapeutics' Satri-cel, the world's first CAR-T treatment for solid tumors, and Neuracle Medical Technology's implantable brain-computer interface system.
The Indian market closed with modest gains on April 23, marking its third consecutive higher session, despite last-hour profit booking that erased most of the day's initial gains. The Sensex rose 0.12% and the Nifty gained 0.14%, driven by positive global cues and strong performance in broader markets.
Eli Lilly is acquiring psychedelic drug maker AtaiBeckley for up to $3.8 billion, indicating Big Pharma's growing interest in these treatments for mental health. This follows positive clinical trial results and a Trump executive order to fast-track FDA reviews, despite past regulatory hurdles.
High street pharmacies in England are now providing a free Meningitis B vaccine to young people aged 17-25, including university and college students. This initiative follows a significant outbreak in Kent earlier this year, aiming to protect those most at risk.
Bayer erzielt mit Apollo einen Milliarden-Deal, um finanziellen Spielraum zu gewinnen. Der Konzern bringt sein Geschäft mit Langzeit-Kontrazeptiva in eine neue Gesellschaft ein und erhält dafür 3,0 Milliarden Euro Eigenkapital.
Deutschland droht, seine führende Position in der Pharmaindustrie durch das geplante Beitragssatzstabilisierungsgesetz der gesetzlichen Krankenkassen zu gefährden. Trotz starker Exporte und akademischen Erfindergeists könnte dies zu einem Verlust von Arbeitsplätzen führen.
Natco Pharma announced a nearly Rs 2,500 crore investment in South Africa, including Rs 1,400 crore for its local subsidiary. The company will also increase its stake in Adcock Ingram to 49% for Rs 1,069 crore, aiming to expand its geographic footprint.
An FDA panel is set to review seven peptides, popular in wellness circles for injury recovery and more, but lacking large-scale trials and FDA approval. Concerns linger about safety and potential conflicts of interest among panel members.
South Korea's biopharmaceutical exports are projected to reach a record high in the first half of this year, with an estimated $4.5 billion in shipments, a 15.3% increase. The sector's growth is driven by recombinant protein drugs, with key export markets including Switzerland, the United States, and Hungary.
A midtown Manhattan building was evacuated Tuesday after structural steel beams began bending, prompting officials to establish a collapse zone. Tourists and locals scrambled for accommodation as nearby hotels and buildings were also evacuated as a precaution. No injuries were reported.
A midtown Manhattan building was evacuated Tuesday after structural issues caused steel beams to bend, leading to the creation of a "collapse zone." Tourists and locals were forced to find new accommodations as nearby hotels and buildings were also evacuated as a precaution. No injuries were reported, and emergency repairs have begun.
A midtown Manhattan building was evacuated Tuesday after steel beams began bending, prompting concerns of collapse. Tourists and locals were displaced as emergency repairs began, with officials assessing the unstable structure.
